P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)

• F. J. Hernandez-Ilizaliturri,
• J. Kuruvilla,
• B. A. Christian,
• I. W. Flinn,
• S. E. Assouline,
• M. L. Ulrickson,
• D. J. Landsburg,
• M. Stuart,
• H. Lowman,
• N. Levin,
• D. Maetzel,
• N. N. Viller,
• A. MacLaren

Affiliations

F. J. Hernandez-Ilizaliturri

1 Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, United States of America

J. Kuruvilla

2 The Princess Margaret Hospital, Toronto, ON, Canada

B. A. Christian

3 The Ohio State University, Columbus, OH

I. W. Flinn

4 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States of America

S. E. Assouline

5 Division of Hematology, Sir Mortimer B. Davis-Jewish General Hospital, Department of Oncology, McGill University, Montreal, QC, Canada

M. L. Ulrickson

6 Banner MD Anderson Cancer Center, Gilbert, AZ

D. J. Landsburg

7 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

M. Stuart

8 Triphase Accelerator, La Jolla, CA, United States of America

H. Lowman

8 Triphase Accelerator, La Jolla, CA, United States of America

N. Levin

8 Triphase Accelerator, La Jolla, CA, United States of America

D. Maetzel

9 Triphase Accelerator, Toronto, ON, Canada

N. N. Viller

9 Triphase Accelerator, Toronto, ON, Canada

A. MacLaren

8 Triphase Accelerator, La Jolla, CA, United States of America